DYRK2 and breast carcinoma: In response to chemotherapeutic agents, DYRK2 facilitates phosphorylation-mediated degradation of neurogenic locus notch homolog protein 1 (NOTCH1), which acts as an antiproliferative mechanism in breast cancer cells (31).